Measles at a 35-Year High Is the Bill for MAHA's Vaccine Policy Experiment

2,318 confirmed measles cases as of July 23. That figure, drawn from CDC data and reported by U.S. News and Reuters, already exceeds every annual total since the disease was declared eliminated in the United States in 2000. It is a 35-year high. Roughly 93% of this year's cases are in people who were unvaccinated or whose vaccination status is unknown, and the large majority are younger than 20, per CDC data reported by Stateline. Numbers like these do not settle policy arguments on their own, but they set the terms of one, and the argument that needs settling in 2026 is whether the "Make America Healthy Again" rewrite of federal vaccine policy is buying anything worth this price. Our answer, on the evidence now available, is no.

Numbers Before Arguments

Consider the baseline erosion first, because the outbreak did not materialize from nowhere. National kindergarten vaccination coverage fell to 92.5% in the 2024-25 school year from 95.2% in 2019-20, below the roughly 95% threshold epidemiologists consider necessary to block sustained measles transmission. Per CIDRAP's ongoing tracking, at least 33 states are now under that threshold for kindergartners, up from 28 before the pandemic. Mississippi, a former national leader in coverage, recorded its first pertussis death in 13 years. This past flu season produced at least 52 pediatric deaths. Each data point has proximate local causes, and coverage was already sliding before this administration took office. But they now share a federal context: a government that has spent the past year telling Americans that fewer routine immunizations deserve official endorsement. When federal vaccine policy signals doubt, hesitancy that once lived at the margins acquires an official imprimatur, and the marginal parent who might have kept an appointment quietly stops making them.

Elimination Status Clock Runs Out in November

There is a deadline attached to all of this, and it is four months away. The Pan American Health Organization's Regional Verification Commission for measles, rubella and congenital rubella syndrome will assess whether the United States still meets the criteria for elimination when it convenes in November, a review originally scheduled for April 2026 and postponed, as CNN and PAHO both reported. The technical test is narrow: elimination requires interruption of endemic transmission for at least 12 consecutive months under high-quality surveillance, per KFF's explainer of the standard. Whole-genome sequencing is doing the deciding. Investigators have traced a continuous phylogenetic chain from the January 2025 outbreak in West Texas through later clusters in Utah, South Carolina and additional states, the signature of sustained domestic spread rather than repeated importation. KFF puts the imported share of cases at 10% in 2025 and 6% so far in 2026.

Canada has already crossed that line, losing its endemic-free standing in November 2025 after the commission concluded transmission had re-established there. CDC figures reported by NBC News put the United States at 2,318 confirmed cases across 45 jurisdictions this year, with 35 new outbreaks and 93% of cases outbreak-associated, and no measles deaths recorded so far in 2026 following three in 2025. Losing elimination status rewrites no statute and unlocks no money. What it changes is the baseline assumption behind every school policy, clinical protocol and travel advisory in the country: measles would once again be something circulating here rather than something arriving here.

Schedule Rewrite That Sidelined the Experts

Recall how that context was built. In June 2025, Health Secretary Robert F. Kennedy Jr. removed all 17 sitting members of the Advisory Committee on Immunization Practices and installed replacements, a move PBS NewsHour documented in detail. The reconstituted panel voted to end the universal recommendation for covid vaccination, shifting people six months and older to "shared clinical decision-making." Then, on January 5, 2026, an acting CDC director signed a memo cutting the universally recommended childhood schedule from 17 diseases to 11, downgrading covid, hepatitis A and B, rotavirus, influenza and meningococcal vaccines to high-risk or discuss-with-your-doctor status. NBC News reported the overhaul was explicitly modeled on Denmark's leaner schedule, and that the memo bypassed the advisory committee altogether. The new ACIP chair, Kirk Milhoan, has said the panel is "reevaluating all of the vaccine products." Reevaluation sounds unobjectionable. Removing recommendations first and evaluating afterward is something else.

Choice Language, Coverage Consequences

Defenders of the MAHA agenda describe all this as restoring individual choice, and the phrase "shared clinical decision-making" is engineered to sound like empowerment. The engineering conceals a mechanism. Federal statutes tie insurance obligations directly to ACIP recommendations: the Vaccines for Children program, Medicaid and CHIP coverage, and private insurers' no-cost-sharing requirements all key off the committee's official list, as Georgetown University's Center for Children and Families laid out in its analysis of this spring's litigation. Downgrade a recommendation and you do not merely change advice; you put the shot's funding at risk for the families least able to pay out of pocket.

Access tells the same story. The Commonwealth Fund has documented how the federal changes pushed covid vaccination back toward prescription gatekeeping, and by September 2025 roughly 25 states barred pharmacists from administering covid shots without a prescription. A vaccine that requires a doctor's visit, a prescription and possibly an out-of-pocket payment is not a freer choice than one available at any pharmacy counter. It is the same choice with a higher price, and higher prices fall hardest on low-income and rural families. That is the quiet redistribution inside the choice rhetoric: vaccine policy framed as liberty operates, in practice, as rationing by friction.

Price Tag Nobody Budgeted For

Prevention arguments usually lose to budget arguments, so the fiscal side belongs on the record. A Yale School of Public Health team estimated that the 2025 measles resurgence cost roughly $244.2 million, or about $104,629 per case, in an analysis reported by CIDRAP. Outbreak response work (contact tracing, testing and post-exposure vaccination) accounted for 65.2% of that total, productivity losses from missed work and school for 32.1%, and direct medical care for just 3.0%. Almost all of the money, in other words, goes to chasing a disease rather than treating it. The same researchers projected that if coverage keeps sliding by one percentage point a year over five years, annual costs would reach roughly $1.5 billion by 2030, with a cumulative five-year bill near $7.8 billion.

State ledgers already show the pattern. Writing in Forbes, Brian Castrucci, president and chief executive of the de Beaumont Foundation, reported that South Carolina spent about $2.1 million in 2026 responding to close to 1,000 measles cases, and argued that outbreak spending operates as an unlegislated tax: money pulled away from maternal health, overdose prevention and foodborne illness work, plus premium effects and business disruption that reach households regardless of their own vaccination decisions. Vaccine policy sold as deregulation has produced one of the least efficient categories of public spending available, reactive containment at six figures per case.

Parallel System Built by Courts and Pediatricians

Institutions have started routing around the federal government, which is its own kind of indictment. On March 16, 2026, a federal court issued a preliminary injunction staying the January schedule memo and the new ACIP appointments, restoring the June 2024 schedule; the court found the plaintiffs likely to succeed on the claim that the CDC cannot bypass the statutorily named committee, per Georgetown's summary of the order. The underlying suit, brought by the American Academy of Pediatrics against Secretary Kennedy, survived a motion to dismiss in January and continues. Meanwhile the AAP published its own 2026 schedule covering 18 diseases, twelve major medical organizations endorsed it, and a majority of states formally adopted it over the federal version, according to CIDRAP and AAP News.

Some MAHA sympathizers read that split as pluralism. We read it as fragmentation with a body count pending. A national immunization schedule is valuable precisely because it is national: pediatricians, insurers, school districts and state health departments all coordinate on one authoritative document. America now has two, plus a court order determining which one is operative this month. Families get conflicting signals depending on which state they live in and which news source they trust. Uncertainty of that kind does not produce carefully individualized decisions. It produces missed appointments, and missed appointments produce the case counts this column opened with. Fragmented vaccine policy also corrodes something harder to rebuild than coverage rates: the shared presumption, held for decades across party lines, that the immunization schedule was a technical document rather than a political one.

Litigation Calendar and the Supreme Court Risk

The March injunction did not end the matter, and it is now on appeal. U.S. District Judge Brian E. Murphy found that Kennedy's schedule changes and his reconstitution of the advisory committee likely violated the Administrative Procedure Act, per CIDRAP's account of the ruling. The order stayed the January 5 schedule, reversed the May 2025 secretarial directive on covid vaccine recommendations, undid the hepatitis B downgrade adopted at the December 2025 ACIP meeting, and barred the committee from meeting again until the court rules on the legality of its membership. The American Public Health Association, announcing the decision, treated that last provision as the operative one: an advisory panel that cannot convene cannot keep rewriting the schedule.

HHS is appealing on an expedited briefing schedule while the district court proceeds in parallel. Department spokesperson Andrew Nixon said the government looks "forward to this judge's decision being overturned just like his other attempts to keep the Trump administration from governing," per CIDRAP. Richard Hughes IV, a vaccine law attorney quoted in the same report, expects the administration to seek Supreme Court intervention on the emergency docket if the appeals court rules against it, with a merits decision plausible in the October 2026 term. On that timetable the schedule governing American childhood vaccine policy could change twice more before the 2027-28 school year begins, which is exactly the instability pediatricians say pushes families to postpone appointments.

States Assembling Their Own Guidance Machinery

While the federal case proceeds, states have been building substitutes. MultiState's review of 2025 activity counts two interstate blocs now issuing coordinated guidance: the West Coast Health Alliance (California, Hawaii, Oregon and Washington) and the Northeast Public Health Collaborative (Connecticut, Delaware, Maine, Maryland, Massachusetts, New Jersey, New York State, New York City, Pennsylvania, Rhode Island and Vermont), covering fourteen states between them. The West Coast group's first act was joint guidance on covid, flu and RSV vaccination that went beyond what ACIP had endorsed. California went further: Governor Gavin Newsom signed AB 144, which lets the state key its rules to recommendations from independent bodies such as the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists rather than to the federal committee alone. At least 18 states moved to protect access in 2025, KFF's tracker shows, while Florida moved the other way and worked to roll back school vaccination mandates outright.

None of that substitutes for a functioning national schedule, and the coverage numbers suggest the substitutes are not holding the line. CDC figures reported by AAP News put the kindergarten exemption rate at a record 3.6% for 2024-25, up from 3.3% a year earlier, with 17 states above 5% and the rise driven almost entirely by nonmedical exemptions. National MMR coverage of 92.5% missed the Healthy People 2030 goal for a fifth consecutive year and left roughly 286,000 kindergartners unprotected in a single cohort. Vaccine policy written state by state can preserve access for families who go looking for it. It cannot rebuild a default.

Trade-Off Ledger the Administration Will Not Publish

Every public health regime involves trade-offs, and an honest version of this administration's vaccine policy would state its own: accept some rise in vaccine-preventable disease in exchange for gains in trust, transparency or safety science. But the promised gains keep failing to appear on the ledger. The Vaccine Injury Compensation Program, the system that actually serves people harmed by vaccines, has been hollowed rather than strengthened; Kennedy dismissed at least half its advisory panel, which met only once in all of 2025, per CIDRAP's reporting. Trust has not measurably recovered; coverage keeps falling. What the country has received so far is the cost side alone: a 35-year measles high, three measles deaths in 2025, herd immunity breached in most states, and a coverage architecture thrown into litigation.

Opinion columns should say plainly what they want. Here is our list. Restore the statutory role of a professionally qualified advisory committee and let its recommendations, whatever they turn out to be, flow through the coverage machinery Congress built. Publish the evidence reviews before changing the schedule, not after. And retire the pretense that dismantling defaults expands freedom. Defaults are how a complex society delivers prevention at scale. Vaccine policy that abandons them is not making America healthy again. The 2026 case counts are what it is making instead.